8-K
filed June 4, 2026, 4:06 PM ET
ticker KLRS
CIK 0001754068
other material
confidence high
sentiment neutral
materiality 0.15
Kalaris Therapeutics holds 2026 annual meeting; all proposals pass
Kalaris Therapeutics, Inc.
- Elected Napoleone Ferrara, David Hallal, Leone Patterson as Class III directors (three-year terms).
- Advisory vote on executive compensation approved: 15.85M for, 0.50M against.
- Shareholders recommended say-on-pay every year; board adopts annual frequency.
- Ratified Deloitte & Touche as auditor for FY 2026: 19.77M for, 1.58K against.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Kalaris Therapeutics, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-03 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-03
Exact text from the filing
The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Kalaris Therapeutics, Inc. shareholders approved Advisory vote on the frequency of future advisory votes on executive compensation at the 2026-06-03 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2026-06-03
Exact text from the filing
The stockholders of the Company recommended, on a non-binding advisory basis, that future advisory votes on the compensation of the Company's named executive officers be held every year.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Kalaris Therapeutics, Inc. shareholders approved Election of Class III directors Napoleone Ferrara, M.D., David Hallal and Leone Patterson at the 2026-06-03 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-03
Exact text from the filing
The stockholders of the Company elected Napoleone Ferrara, M.D., David Hallal and Leone Patterson as Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Kalaris Therapeutics, Inc. shareholders approved Advisory vote on the compensation of the Company's named executive officers at the 2026-06-03 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-03
Exact text from the filing
The stockholders of the Company approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.